This week, a number of companies, big and small, shared updates on their cardiovascular technology innovations at EuroPCR ...

Elixir Medical announced three-year results from a large randomized controlled trial of its DynamX coronary bioadaptor system.

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

Clinical follow-up will continue through five years. BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX® bioadaptor clinical evidence program consisting of nine company ...

KUALA LUMPUR, April 28 (Bernama) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, has announced the first clinical use of its LithiX Hertz Contact (HC) ...

MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiXTM ...

First cases completed by Dr. Tamil Selvan Muthusamy, MD, and Dr. Rosli Mohd Ali, MD, and transmitted live at TCTAP Congress in Seoul, Korea. Novel IVL technology designed to deliver calcium ...

MILPITAS, Calif., April 25, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced the first clinical use of its LithiX™ Hertz ...

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

Image credit: Shutterstock / doomu. Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs ...